Journal of Medicinal Chemistry
Article
(9) Exton, J. H.; Park, C. R. D. The Stimulation of Gluconeogenesis
from Lactate by Epinephrine, Glucagon and Cyclic 3′,5′-Adenylate in
the Perfused Rat Liver. Pharmacol. Rev. 1966, 18, 181.
(10) DeMong, D. E.; Miller, M. W. Glucagon Receptor Antagonists
in Development. In RSC Drug Discovery Series, Issue 27; New
Therapeutic Strategies for Type 2 Diabetes; Jones, R., Ed.; The Royal
Society of Chemistry: Cambridge, UK, 2012; pp 429−463.
(11) Shen, D.-M.; Lin, S.; Parmee, E. R. A Survey of Small Molecule
Glucagon Receptor Antagonists from Recent Patents (2006−2010).
Expert Opin. Ther. Pat. 2011, 21, 1211−1240.
Dependent Insulinotropic Polypeptide Receptor. J. Med. Chem. 2008,
51, 5387−5396.
(24) Shen, D.-M.; Zhang, F.; Brady, E. J.; Candelore, M. R.; Dallas-
Yang, Q.; Ding, V. D.-H.; Dragovic, J.; Feeney, W. P.; Jiang, G.;
McCann, P. E.; Mock, S.; Qureshi, S. A.; Saperstein, R.; Shen, X.;
Tamvakopoulos, C.; Tong, X.; Tota, L. M.; Wright, M. J.; Yang, X.;
Zheng, S.; Chapman, K. T.; Zhang, B. B.; Tata, J. R.; Parmee, E. R.
Discovery of Novel, Potent, And Orally Active Spiro-Urea Human
Glucagon Receptor Antagonists. Bioorg. Med. Chem. Lett. 2005, 15,
4564−4569.
(25) For key references regarding the preparation of imidazolone N-
oxides, see: (a) Pernet-Poil-Chevrier, A.; Cantagrel, F.; Le Jeune, K.;
Philouze, C.; Chavant, P. Y. New Chiral Nitrones as Precursors of α,α-
Disubstituted Amino-Acids, According to the SRS Principle.
Tetrahedron: Asymmetry 2006, 17, 1969−1974. (b) Cheng, S.; Wu,
H.; Hu, X. Versatile Spirocyclic Glycine-Based Nitrones and Their
Highly Stereoselective 1,3-Dipolar Cycloaddition. Synth. Commun.
2007, 37, 297−308. (c) Aouadi, K.; Jeanneau, E.; Msaddek, M.; Praly,
J.-P. Analogues of Insulin Secretagogue (2S,3R,4S)-4-Hydroxyisoleu-
cine: Synthesis by 1,3-Dipolar Cycloaddition Reactions of Chiral
Nitrones to Alkenes. Tetrahedron: Asymmetry 2008, 19, 1145−1152.
(26) DeMong, D. E.; Ng, I.; Miller, M. W.; Stamford, A. W. A Novel
Method for the Preparation of 4-Arylimidazolones. Org. Lett. 2013, 15,
2830−2833.
(27) Cogan, D. A.; Liu, G.; Ellman, J. Asymmetric Synthesis of Chiral
Amines by Highly Diastereoselective 1,2-Additions of Organometallic
Reagents to N-tert-Butanesulfinyl Imines. Tetrahedron 1999, 55,
8883−8904.
(28) Higashibayashi, S.; Tohmiya, H.; Mori, T.; Hashimoto, K.;
Nakata, M. Synthesis of Sulfinimines by Direct Condensation of
Sulfinamides with Aldehydes Using Cs2CO3 as an Activating and
Dehydrating Reagent. Synlett 2004, 457−460.
(12) DeMong, D. E.; Miller, M. W.; Lachowicz, J. E. Glucagon
Receptor Antagonists for Type II Diabetes. In Annual Report on
Medicinal Chemistry; Macor, J. E., Ed.; Academic Press: London, UK,
2008; Vol. 43, pp 119−137.
(13) Sloop, K. W.; Michael, M. D.; Moyers, J. S. Glucagon as a Target
for the Treatment of Type 2 Diabetes. Expert Opin. Ther. Pat.ents
2005, 9, 593−600.
(14) Ling, A. L.; Wasserman, J. I. Approaches to Glucagon Receptor
Antagonists. Expert Opin. Ther. Pat. 2003, 13, 15−22.
(15) Petersen, K. F.; Sullivan, J. T. Effects of a Novel Glucagon
Receptor Antagonist (Bay 27-9955) On Glucagon-Stimulated Glucose
Production in Humans. Diabetologia 2001, 44, 2018−2024.
(16) Xiong, Y.; Guo, J.; Candelore, M. R.; Liang, R.; Miller, C.;
Dallas-Yang, Q.; Jiang, G.; McCann, P. E.; Qureshi, S. A.; Tong, X.;
Xu, S. S.; Shang, J.; Vincent, S. H.; Tota, L. M.; Wright, M. J.; Yang, X.;
Zhang, B. B.; Tata, J. R.; Parmee, E. R. Discovery of a Novel Glucagon
Receptor Antagonist N-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-
methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-
alanine (MK-0893) for the Treatment of Type II Diabetes. J. Med.
Chem. 2012, 55, 6137−6148.
(17) Parmee, E. R. Discovery of MK-0893: A Glucagon Receptor
Antagonist for the Treatment of Type II Diabetes. Abstracts of Papers,
241st ACS National Meeting & Exposition; Anaheim, CA, United States,
March 27−31, 2011; MEDI-31.
(18) Ruddy, M.; Pramanik, B.; Lunceford, J.; Li, S.; Cilissen, C.;
Stoch, S. A.; Wagner, J.; Amatruda, J.; Herman, G.; Kaufman, K.
Inhibition of Glucagon-Induced Hyperglycemia Predicts Glucose
Lowering Efficacy of a Glucagon Receptor Antagonist, MK-0893, in
Type 2 Diabetes (T2DM). Abstracts of 71st Scientific Sessions of the
American Diabetes Association; June 24−28, 2011; Abstract number
0311-OR.
(19) Engel, S. S.; Xu, L.; Andryuk, P. J.; Davies, M. J.; Amatruda, J.;
Kaufman, K.; Goldstein, B. J. Efficacy and Tolerability of MK-0893, a
Glucagon Receptor Antagonist (GRA), in Patients with Type 2
Diabetes (T2DM). Abstracts of 71st Scientific Sessions of the American
Diabetes Association; June 24−28, 2011; Abstract number 0309-OR.
(20) Tham, L. S.; Abu-Raddad, E. J.; Lim, C. N.; Loh, M. T.; Ng, W.
T.; Pinaire, J. A.; Kelley, R. P. The Glucagon Receptor Antagonist
LY2409021 Attenuates Increases in Hepatic Glucose Output (HGO)
and Blood Glucose during Hyperglucagonemia in Healthy Male
Subjects. Abstracts of 71st Scientific Sessions of the American Diabetes
Association; June 24−28, 2011; Abstract number 0416PP.
(21) Kelley, R. P.; Garhyan, P.; Abu-Raddad, E. J.; Fu, H.; Lim, C. N.;
Prince, M. J.; Pinaire, J. A.; Loh, M. T.; Deeg, M. A. Short-Term
Treatment with Glucagon Receptor Antagonist LY2409021 Effectively
Reduces Fasting Blood Glucose (FBG) and HbA1c in Patients with
Type 2 Diabetes Mellitus (T2DM). Abstracts of 71st Scientific Sessions
of the American Diabetes Association, June 24−28, 2011; Abstract
number 0305OR.
(22) Lau, J.; Behrens, C.; Sidelmann, U. G.; Knudsen, L. B.; Lundt,
B.; Sams, C.; Ynddal, L.; Brand, C. L.; Pridal, L.; Ling, A.; Kiel, D.;
Plewe, M.; Shi, S.; Madsen, P. New β-Alanine Derivatives Are Orally
Available Glucagon Receptor Antagonists. J. Med. Chem. 2007, 50,
113−128.
(23) Kodra, J. T.; Steen Jorgensen, A.; Andersen, B.; Behrens, C.;
Lehn Brand, C.; Thoeger Christensen, I.; Gulbrandt, M.; Bekker
Jeppesen, C.; Knudsen, L. B.; Madsen, P.; Nishimura, E.; Sams, C.;
Sidelmann, U. G.; Pedersen, R. A.; Lynn, F. C.; Lau, J. Novel Glucagon
Receptor Antagonists with Improved Selectivity over the Glucose-
2610
dx.doi.org/10.1021/jm401858f | J. Med. Chem. 2014, 57, 2601−2610